^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Breast Cancer
    Drug:tamoxifen (Estrogen receptor antagonist)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: B - Late Trials
    New
    Source:
    Cancer Res
    Title:

    Complete Sequencing of TP53 Predicts Poor Response to Systemic Therapy of Advanced Breast Cancer

    Excerpt:
    TP53 gene mutation was related with a poor response to up-front chemotherapy in our small series of patients (OR, 0.34) and was similarly but significantly related with a poor response to first-line tamoxifen treatment in both univariate analysis (OR, 0.22; P < 0.0001) and multivariate analysis.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

    Excerpt:
    ...- High or moderate penetrance risk pathogenic or likely pathogenic germline gene mutation in ATM, BARD1, BRIP1, CDH1, CHEK2, MSH6, NBN, NF1, PTEN, PMS2, RAD51C, RAD51D, or TP53...
    Trial ID:
    NCT05941520